COMBIVENT RESPIMAT Rx
Generic Name and Formulations:
Ipratropium bromide 20mcg, albuterol 100mcg (equivalent to 120mcg albuterol sulfate); per actuation; inhalation spray; CFC-free.
Boehringer Ingelheim Pharmaceuticals
Indications for COMBIVENT RESPIMAT:
COPD when a second aerosol bronchodilator is needed.
1 inh 4 times daily; max 6 inh/day.
Avoid excessive use. Discontinue if paradoxical bronchospasm occurs. Cardiovascular disorders. Arrhythmias. Hypertension. Diabetes. Hyperthyroidism. Seizure disorders. Sensitivity to sympthomimetic amines. Narrow angle glaucoma. GI or GU obstruction. Hepatic or renal disease. Pregnancy (Cat. C). Labor & delivery. Nursing mothers: not recommended.
Extreme caution within 2 weeks of MAOIs or tricyclic antidepressants (increased cardiovascular effects). Caution with other anticholinergics, sympathomimetics, drugs that lower serum potassium. Antagonized by beta-blockers.
Anticholinergic + beta-2 agonist.
Upper respiratory infection, nasopharyngitis, cough, bronchitis, headache, dyspnea; paradoxical bronchospasm, urinary retention, hypokalemia, hypersensitivity reactions, ocular effects.
Ipratropium bromide: renal.
Inhaler—4g (120 inh)
Endocrinology Advisor Articles
- Clinicians May Be Overtreating Older Patients With Diabetes
- Obesity Risk in Infants Born to Women With Diabetes
- Increased Risk for Mortality in People With Diabetes, CHD Taking Beta-Blockers
- Autism Does Not Affect Metabolic Control in Type 1 Diabetes
- Prediabetes a Useful Indicator for Cardiovascular and Renal Risks